HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delecluse, H-J Articles by Hammerschmidt, W Search for Related Content PubMed PubMed Citation Articles by Delecluse, H-J Articles by Hammerschmidt, W

The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy

¹ GSF-National Research Center for Environment and Health, Institute of Clinical Molecular Biology and Tumor Genetics, Department Gene Vectors, Marchioninistr. 25, D-81377 München, Germany

Correspondence: Professor Delecluse, Department of Pathology, The University of Birmingham, The Medical School, Edgbaston, Birmingham B15 2TT, UK h.delecluse{at}bham.ac.uk

The Epstein-Barr virus (EBV) infects humans and the genome of this infectious agent has been detected in several tumour types, ranging from lymphomas to carcinomas. The analysis of the functions of the numerous viral proteins encoded by EBV has been impeded by the large size of the viral genome, which renders the construction of viral mutants difficult. To overcome these limitations, several genetic systems have been developed that allow the modification of the viral genome. Two different approaches, depending on the host cell type in which the viral mutants are generated, have been used in the past. Traditionally, mutants were constructed in EBV infected eukaryotic cells, but more recently, approaches that make use of a recombinant EBV cloned in Escherichia coli have been proposed. The phenotype associated with the inactivation or modification of nearly 20 of the 100 EBV viral genes has been reported in the literature. In most of the reported cases, the EBV latent genes that mediate the ability of EBV to immortalise infected cells were the targets of the genetic analysis, but some virus mutants in which genes involved in DNA lytic replication or infection were disrupted have also been reported. The ability to modify the viral genome also opens the way to the construction of viral strains with medical relevance. A cell line infected by a virus that lacks the EBV packaging sequences can be used as a helper cell line for the encapsidation of EBV based viral vectors. This cell line will allow the evaluation of EBV as a gene transfer system with applications in gene therapy. Finally, genetically modified non-pathogenic strains will provide a basis for the design of an attenuated EBV live vaccine.

Key Words: Epstein-Barr virus • gene therapy

This article has been cited by other articles:

				M. A. Calderwood, A. M. Holthaus, and E. Johannsen The Epstein-Barr Virus LF2 Protein Inhibits Viral Replication J. Virol., September 1, 2008; 82(17): 8509 - 8519. [Abstract] [Full Text] [PDF]

				D. S. H. Chew, K. P. Choi, and M.-Y. Leung Scoring schemes of palindrome clusters for more sensitive prediction of replication origins in herpesviruses Nucleic Acids Res., September 1, 2005; 33(15): e134 - e134. [Abstract] [Full Text] [PDF]

				T. Kanda, M. Yajima, N. Ahsan, M. Tanaka, and K. Takada Production of High-Titer Epstein-Barr Virus Recombinants Derived from Akata Cells by Using a Bacterial Artificial Chromosome System J. Virol., July 1, 2004; 78(13): 7004 - 7015. [Abstract] [Full Text] [PDF]

				P G Murray and L S Young Themed issue: the biology and pathology of the Epstein-Barr virus Mol. Pathol., October 1, 2000; 53(5): 219 - 221. [Full Text]